Actively Recruiting
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Led by Celgene · Updated on 2026-02-02
62
Participants Needed
22
Research Sites
86 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).
CONDITIONS
Official Title
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older with relapsed and refractory multiple myeloma treated with 2 to 4 prior therapies (Phase 1) or 1 to 3 prior therapies (Phase 2)
- Measurable multiple myeloma confirmed by local lab tests
- Eastern Cooperative Oncology Group performance status of 0 to 1
- Adherence to contraception requirements
You will not qualify if you...
- Prior treatment with mezigdomide
- Prior treatment with T cell engaging therapies
- Prior B cell-maturation antigen (BCMA)-targeting therapy except autologous BCMA-targeted CART-cell therapy given more than 6 months before study
- Other protocol-defined inclusion or exclusion criteria apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 22 locations
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294-3300
Actively Recruiting
2
Yale New Haven Hospital-Smilow Cancer Center
New Haven, Connecticut, United States, 06510
Actively Recruiting
3
Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
Actively Recruiting
4
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
5
Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, Canada, T2N 5G2
Actively Recruiting
6
Local Institution - 0026
Vancouver, British Columbia, Canada, V5Z 4E6
Not Yet Recruiting
7
Local Institution - 0027
Halifax, Nova Scotia, Canada, B3H 2Y9
Not Yet Recruiting
8
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
9
Local Institution - 0030
Suzhou, Jiangsu, China, 215006
Not Yet Recruiting
10
Local Institution - 0031
Shanghai, Shanghai Municipality, China, 200434
Not Yet Recruiting
11
Universitaetsklinikum Carl Gustav Carus Dresden
Dresden, Germany, 01307
Actively Recruiting
12
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, Germany, 20246
Actively Recruiting
13
Universitaetsklinikum Heidelberg
Heidelberg, Germany, 69120
Actively Recruiting
14
Evangelismos General Hospital of Athens
Athens, Attikí, Greece, 106 76
Actively Recruiting
15
Alexandra General Hospital of Athens
Athens, Attikí, Greece, 115 28
Actively Recruiting
16
St. Olavs Hospital
Trondheim, Sør-Trøndelag, Norway, 7030
Actively Recruiting
17
Sykehusapoteket Ull
Oslo, Norway, 0450
Actively Recruiting
18
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, Spain, 39008
Actively Recruiting
19
Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca
Salamanca, Spain, 37007
Actively Recruiting
20
University College London Hospital
London, England, United Kingdom, W1T 7HA
Actively Recruiting
21
Royal Marsden Hospital (Sutton)
London, Sutton, United Kingdom, SM2 5PT
Actively Recruiting
22
The Christie NHS Foundation Trust
Manchester, United Kingdom, M20 4BX
Actively Recruiting
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
F
First line of the email MUST contain the NCT# and Site #.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here